References
- Alharbi KK (2015). Clinical efficacy and possible applications of genomics in lung cancer. Asian Pac J Cancer Prev, 16, 1693-8. https://doi.org/10.7314/APJCP.2015.16.5.1693
- Carey KD, Garton AJ, Romero MS, et al (2006). Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res, 66, 8163-71. https://doi.org/10.1158/0008-5472.CAN-06-0453
- Ciuleanu T, Brodowicz T, Zielinski C, et al (2009). Maintenance pemetrexed plus best supportive care versus placebo plus best sup- portive care for non-small-cell lung cancer:a randomized,double-blind,phase 3 study. Lancet, 374, 1432-40. https://doi.org/10.1016/S0140-6736(09)61497-5
- Di BS, Wei KP, Tian JH, et al (2014). Effectiveness and safety of pemetrexed versus docetaxel as a treatment for advanced small cell lung cancer: a systematic review and metaanalysis. Asian Pac J Cancer Prev, 15, 3419-24. https://doi.org/10.7314/APJCP.2014.15.8.3419
- Fukihara J, Watanabe N, Taniguchi H, et al (2014). Clinical predictors of response to egfr tyrosine kinase inhibitors in patients with egfr-mutant non-small cell lung cancer. Oncol, 86, 86-93. https://doi.org/10.1159/000357129
- Giovannetti E, Lemos C, Tekle C, et al (2008). Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells. Mol Pharmacol, 73, 1290-300. https://doi.org/10.1124/mol.107.042382
- Hanna N, Shepherd FA, Fossella FV (2004). Randomized phase III trial of pemetrexed versus docetaxel in patients with nonsmall-cell lung cancer previously treated with chemotherapy. J Clin Oncol, 22, 1589-97. https://doi.org/10.1200/JCO.2004.08.163
- Hasegawa Y, Ando M, Maemondo M, et al (2015). The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials. The Oncologist, 20, 307-15. https://doi.org/10.1634/theoncologist.2014-0285
- Huang XE, Tian GY, Cao J, et al (2014). Pemetrexed as a component of first-, second- and third- line chemotherapy in treating patients with metastatic lung adenocarcinoma. Asian Pac J Cancer Prev, 14, 6663-7.
- Inoue A, Kobayashi K, Maemondo M, et al (2013). Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemonaive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002). Ann Oncol, 24, 54-9. https://doi.org/10.1093/annonc/mds214
- Jiang X, Yang B, Lu J, et al (2015). Pemetrexed-based chemotherapy in advanced lung adenocarcinoma patients with different EGFRgenotypes. Tumour Biol, 36, 861-9. https://doi.org/10.1007/s13277-014-2692-4
- Joerger M, Omlin A, Cerny T, et al (2010). The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action. Curr Drug Targets, 11, 37-47. https://doi.org/10.2174/138945010790030974
- Kubota K, Niho S, Enatsu S, et al (2009). Efficacy differences of pemetrexed by histology in pretreated patients with stage IIIB/IV non-small cell lung cancer: review of results from an open-label randomized phase II study. J Thorac Oncol, 4, 1530-6. https://doi.org/10.1097/JTO.0b013e3181b9e608
- Lee CK, Wu YL, Ding PN, et al (2015). Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysis. J Clin Oncol, 33, 1958-65. https://doi.org/10.1200/JCO.2014.58.1736
- Liu Q, Yu Z, Xiang Y, et al (2015). Prognostic and predictive significance of thymidylate synthase protein expression in non-small cell lung cancer: a systematic review and metaanalysis. Cancer Biomark, 15, 65-78. https://doi.org/10.3233/CBM-140432
- Liu Y, Yin TJ, Zhou R, et al (2013). Expression of thymidylate synthase predicts clinical outcomes of pemetrexedcontainingchemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis. Cancer Chemother Pharmacol, 72, 1125-32. https://doi.org/10.1007/s00280-013-2299-2
- Lynch TJ, Bell DW, Sordella R, et al (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med, 350, 2129-39. https://doi.org/10.1056/NEJMoa040938
- Maemondo M, Inoue A, Kobayashi K, et al (2010). Gefitinib or chemotherapy for non-small-cell lung cancer with mutated egfr. N Engl J Med, 362, 2380-8. https://doi.org/10.1056/NEJMoa0909530
- Matam K, Goud I, Lakshmi M, et al (2015). Correlation between EGFR Gene Mutations and Lung Cancer: a Hospital-Based Study. Asian Pac J Cancer Prev, 16, 7071-6. https://doi.org/10.7314/APJCP.2015.16.16.7071
- Mitsudomi T, Kosaka T, Yatabe Y, (2006). Biological and clinical implications of EGFR mutations in lung cancer. Int J Clin Oncol, 11, 190-8. https://doi.org/10.1007/s10147-006-0583-4
- Mitsudomi T, Morita S, Yatabe Y, et al (2010). Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG 3405): An open label, randomised phase 3 trial. Lancet Oncol, 11, 121-8. https://doi.org/10.1016/S1470-2045(09)70364-X
- Nakamura R, Inage Y, Tobita R, et al (2014). Epidermal growth factor receptor mutations: effect on volume doubling time of non-small-cell lung cancer patients. J Thorac Oncol, 9, 1340-4. https://doi.org/10.1097/JTO.0000000000000022
- Ohe Y, Ichinose Y, Nakagawa K, et al (2008). Efficacy and safety of two doses of pemetrexed supplemented with folic acid and vitamin B12 in previously treated patients with non-small cell lung cancer. Clin Cancer Res, 14, 4206-12. https://doi.org/10.1158/1078-0432.CCR-07-5143
- Ohe Y, Ohashi Y, Kubota K, et al (2007). Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol, 18, 317-23.
- Okami J, Taniguchi K, Higashiyama M, et al (2007). Prognostic factors for gefitinib-treated postoperative recurrence in nonsmall cell lung cancer. Oncol, 72, 234-42. https://doi.org/10.1159/000112947
- Paez JG, Janne PA, Lee JC, et al (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Sci, 304, 1497-500. https://doi.org/10.1126/science.1099314
- Pao W, Miller V, Zakowski M, et al (2004). EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A, 101, 13306-11. https://doi.org/10.1073/pnas.0405220101
- Rossi A, Galetta D, Gridelli C (2014). Biological prognostic and predictive factors in lung cancer. Oncol, 77, 90-6.
- Schiller JH (2001). Current standards of care in small-cell and non-small-cell lung cancer. Oncol, 61, 3-13. https://doi.org/10.1159/000055386
- Schiller JH, Harrington D, Belani CP, et al (2002). Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med, 346, 92-8. https://doi.org/10.1056/NEJMoa011954
- Solomon B, Bunn Jr PA (2005). Clinical activity of pemetrexed: a multitargeted antifolateanticancer agent. Future Oncol, 1, 733-46. https://doi.org/10.2217/14796694.1.6.733
- Wang L, Wang R, Pan Y, et al (2014). The pemetrexedcontaining treatments in the non-small cell lung cancer, is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis. BMC Cancer, 14, 205. https://doi.org/10.1186/1471-2407-14-205
- Wang T, Chuan PC, Rui YJ, et al (2013). Association between TYMS Expression and Efficacy of Pemetrexed-Based Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Meta-Analysis. PLoS One, 8, 74284. https://doi.org/10.1371/journal.pone.0074284
- Wu SG, Yang CH, Yu CJ, et al (2011). Good response to pemetrexed in patients of lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutations. Lung Cancer, 72, 333-9. https://doi.org/10.1016/j.lungcan.2010.10.012
- Yang JC, Wu YL, Schuler M, et al (2015). Afatinib versus cisplatin-based chemotherapy for egfr mutation-positive lung adenocarcinoma (lux-lung 3 and lux-lung 6): Analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol, 16, 141-51. https://doi.org/10.1016/S1470-2045(14)71173-8